Abbott India Ltd.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 6 May 2026. This shift reflects nuanced changes across four critical parameters: quality, valuation, financial trend, and technicals. Despite a challenging recent performance, the company’s strong fundamentals and evolving market signals have prompted a reassessment of its outlook.

Abbott India Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. This change accompanies a 3.84% gain in the stock price on 7 May 2026, reflecting renewed investor interest despite mixed signals from key technical indicators.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an expensive to a very expensive rating. This change reflects evolving market perceptions and raises questions about the stock’s price attractiveness relative to its historical averages and peer group benchmarks.

Abbott India Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Despite a broadly positive market backdrop, Abbott India Ltd. has slid to a fresh 52-week low of Rs 25,164 on 27 Apr 2026, marking a 15.16% decline over the past year and underperforming the Sensex by a wide margin. This divergence raises questions about the underlying factors weighing on the stock amid a rally in mega caps and a Sensex trading 0.43% higher.

Abbott India Ltd. shares declined to a fresh 52-week low of Rs.25,310.5 on 24 April 2026, marking a significant dip amid broader market weakness and company-specific factors. The stock’s fall comes after two days of gains, reflecting a reversal in momentum within the Pharmaceuticals & Biotechnology sector.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Abbott India Ltd. has reached a new 52-week low of Rs.25,315.55 on 22 April 2026, marking a significant decline in its stock price over the past year. This drop comes amid a broader market downturn and reflects a combination of valuation concerns and subdued recent financial performance.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects a recalibration in price attractiveness, driven by elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical averages and peer benchmarks. Investors are now reassessing the stock’s appeal amid a backdrop of mixed returns and sector dynamics.

Abbott India Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its valuation parameters shift notably, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions amid a backdrop of mixed returns and sector comparisons, raising questions about the stock's price attractiveness relative to its peers and historical benchmarks.

Abbott India Ltd. has reached a new 52-week low price of Rs.25,318.3 on 13 April 2026, marking a significant decline amid broader market weakness and company-specific performance factors. The stock has been on a downward trajectory over the past three days, reflecting a -1.19% return during this period and trading below all key moving averages.

Abbott India Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Abbott India Ltd has experienced a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, reflecting a subtle but significant change in price attractiveness. This development comes amid a broader pharmaceutical sector landscape where peer companies display a wide range of valuation multiples, prompting investors to reassess Abbott India's relative appeal.

Abbott India Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 09 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 01 April 2026, providing investors with the latest insights into its performance and outlook.

The Sensex gained 1.95% on 24 Mar 2026, yet Abbott India Ltd. outperformed with a 5.41% surge, touching an intraday high of Rs 27,001.6. This 3.46-percentage-point outperformance signals a stock-specific strength amid a broader market that remains under pressure, raising the question of whether this rally marks a genuine recovery or a technical rebound within a mixed trend.

Abbott India Ltd. shares declined to a fresh 52-week low of Rs.25,350 on 24 March 2026, reflecting a continuation of the stock’s downward trend amid broader market pressures and company-specific valuation concerns.